Updated:
Ocugen
Ocugen is a Malvern, PA-based firm focused on modifier gene therapies and vaccines for retinal diseases and infectious conditions.
Ocugen
Ocugen was established with a focus on discovering and developing gene therapies for ocular diseases. The firm's lead candidate, OCU400, is a modifier gene therapy for retinitis pigmentosa and other retinal dystrophies. Ocugen also entered into an agreement with Bharat Biotech to co-develop and market Covaxin, a COVID-19 vaccine, for the US and Canadian markets (per company announcements, 2022). Ocugen's strategy centers on its modifier gene therapy platform, which aims to address multiple retinal diseases with a single product. The firm has conducted clinical trials in the United States and internationally, with manufacturing and supply chain supported by partners in India. The geographic footprint includes operations in the US and collaboration ties in Asia. As of 2024, Ocugen had not disclosed AUM or headcount publicly. The firm raised capital through equity offerings and stock issuances to fund clinical development. No recent operational event of the last 24 months has been publicly reported. Ocugen's structural differentiator lies in its modifier gene therapy approach, which targets a broad mechanism rather than a single genetic mutation. This contrasts with precision gene therapies that are mutation-specific and may limit addressable patient populations. The firm's reliance on partnership for commercial-scale manufacturing and regulatory expertise in non-US markets shapes its operational model.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Malvern
Corporate office
Malvern, United States
Frequently asked questions
What is Ocugen's primary therapeutic focus?
Ocugen is developing modifier gene therapies for retinal diseases, with lead candidate OCU400 targeting retinitis pigmentosa. The firm also collaborated on a COVID-19 vaccine candidate (Covaxin) through a partnership with Bharat Biotech (per company communications, 2022).
How does Ocugen's modifier gene therapy differ from other gene therapies?
Ocugen's modifier therapy platform aims to restore cellular function across multiple downstream pathways without correcting a specific gene mutation. This contrasts with gene replacement therapies that are disease- or mutation-specific and may have limited applicability across patient populations.
Which partners support Ocugen's manufacturing and distribution?
Ocugen has partnered with Bharat Biotech, an Indian vaccine manufacturer, for Covaxin development and supply. The company has not disclosed other manufacturing partners for its gene therapy programs beyond general contract manufacturing arrangements.
Has Ocugen disclosed its AUM or deployment amount?
No. Ocugen does not publicly report assets under management or deployment figures. The firm funds R&D through equity offerings and strategic partnerships, as disclosed in SEC filings.
What stage of clinical development is Ocugen in?
Ocugen's lead candidate OCU400 was in Phase 3 clinical trials as of 2023, with initial data expected in 2024. The firm also explored regulatory approval for Covaxin under an emergency use authorization pathway in the US.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: